"FDA grants ODD to Tempest’s hepatocellular carcinoma treatment" was originally created and published by Pharmaceutical ...

The following is a summary of “Development models to predict complication and prognosis following liver resection for ...

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • ...

MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.

MAIA Biotechnology (MAIA) announced that it has entered into a clinical supply agreement with BeiGene (BGNE) to assess the efficacy of THIO, ...

BGB-10188 is under clinical development by BeiGene and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase transition ...

Patients with indeterminate chronic hepatitis B (CHB) phase are at risk of progressing to advanced liver disease and hepatocellular carcinoma (HCC), according to study results published in the Journal ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla.

This manuscript offers valuable insights by identifying two distinct liver cancer subtypes through multi-omics integration and developing a robust prognostic model, validated across various datasets, ...

Future directions for the treatment of patients with nonresectable hepatocellular carcinoma from the Bologna Liver Oncology Group (BLOG). Exploring alternative intra-arterial treatments (such as ...